<DOC>
	<DOCNO>NCT02281591</DOCNO>
	<brief_summary>Single centre , open-label , randomise study four parallel group healthy volunteer</brief_summary>
	<brief_title>Disposition Eslicarbazepine Acetate Its Metabolites S-licarbazepine R-licarbazepine</brief_title>
	<detailed_description>Single centre , open-label , randomise study four parallel group healthy volunteer : Group 1 = 900 mg eslicarbazepine acetate ( ESL , BIA 2-093 ) ; Group 2 = 450 mg S-licarbazepine plus 450 mg R-licarbazepine ; Group 3 = 450 mg S-licarbazepine ; Group 4 = 450 mg Rlicarbazepine . In group , study consist single-dose period ( Phase A ) follow repeateddose period 7 day duration investigational product administer daily ( Phase B ) . The repeated-dose phase start 96 h post single-dose .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Inclusion Criteria Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Subjects healthy determine prestudy medical history , physical examination , vital sign , neurological examination , 12lead ECG . Subjects clinical laboratory test clinically acceptable screen admission . Subjects negative test HBsAg , antiHCV Ab HIV1 HIV2 Ab screen . Subjects negative drug abuse alcohol screen admission . Subjects nonsmoker smoke &lt; 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative pregnancy test screen admission Phase A . Subjects conform inclusion criterion , OR Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity ( especially carbamazepine oxcarbazepine ) . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen admission .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>